September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Li­for­di Im­munother­a­peu­tics: Us­ing an­ti­bod­ies to de­liv­er po­tent steroids di­rect­ly to im­mune cells

Ryan Cross

Senior Science Correspondent

↑
  • CEO Arthur Tzian­a­bos
  • To­tal raised $70 mil­lion
  • Head­quar­ters Burling­ton, MA

As a young sci­en­tist, Jay Roth­stein asked fel­low im­mu­nol­o­gists what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times